Benzylpiperazine
Derivatives. A series of 1-benzy1-4-diphenylmethylpiperazines was prepared and tested for cerebral vasodilating activity. Among the compounds with stronger potency and longer-lasting action than papaverine, the most potent analog 19 (KB-2796) was selected for further study. Some pharmacological properties of 19 are presented.
IV.1) Syntheses and Cerebral
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benzylpiperazine; diphenylmethylpiperazine; 1-benzyl-4-diphenylmethylpiperazine; Leuckart-Wallach reaction; cerebral vasodilator; calcium antagonistic activity A considerable body of literature exists on the biological activity of compounds containing the piperazine moiety. In the field of 1-benzyl-4-diphenylmethylpiperazines, antihistaminics,2-4) tranquillizers,5,6) and vasodilators7) have been reported. Some of them, such as buclizine (1), meclizine (2) and medibazine (3), have been used clinically. More recently, 1-diphenylmethyl-4-(4-hydroxybenzyl)piperazines (4) were disclosed to be useful in the treatment of disturbance of cerebral blood flow. 8) In the course of our studies aimed at finding novel cerebral vasodilators,9) 1-diphenylmethy1-4-(2,3,4-trimethoxybenzyl)piperazine (5) was found to possess considerable activity. This compound was described in the patent literature but nothing about its medical utility was disclosed. 10) This paper is concerned with the syntheses of novel analogs of 5 and their evaluation as potential cerebral vasodilators.
Chemistry
Most of the compounds were synthesized by three general methods according to Chart 2. In method A, a substituted benzyl chloride was allowed to react with a diphenylmethylpiperazine derivative in the presence of triethylamine. In method B, which is an application of the Leuckart-Wallach reaction,") a substituted benzaldehyde was condensed reductively with a diphenylmethylpiperazine derivative by the use of formic acid without a solvent. In method C, 1-(2,3,4-trimethoxybenzyl)piperazine (X = 2,3,4-tri-OMe; trimetazidine)12) was allowed to react with diphenylmethyl chloride derivatives, which were prepared from diphenylmethanols") by chlorination with thionyl chloride.
Compounds 15, 17 and 35 were obtained by acetylation of 13, 4a and 31, respectively, and 13 was obtained from 16 by reduction with SnC12-HC1. Diphenylmethylpiperazine derivatives were prepared according to the literature.14)
All the compounds prepared were converted to acid addition salts and purified by recrystallization.
Results
and Discussion
All the compounds listed in Table I except for 16, which was practically insoluble, were tested for cerebral vasodilating activity by the method reported previously. 9) In the case Y = Z = H (3-18), the potency decreased in the following order: 7 (X = 2,4,6-tri-OMe) >5 (X = 2,3,4-tri-OMe) > 4a (X = OH). These compounds did not exhibit longlasting effects (a compound was judged to be long-acting when it exhibited more than 20 times longer duration of action than papaverine). Duration of action and cerebrovascular specificity are considered to be important for cerebral vasodilators.15) Other compounds were less potent No. 8 Vol. 35 (1987) than papaverine. In summary, from the standpoint of stronger activity as well as longer-lasting effect than papaverine, five compounds (19, 23, 29, 34 and 40) were found. However, acute toxicity data indicated that 34 (LD50 = 60 mg/kg) is harmful. Among the remaining four compounds , the most potent 19 (KB-2796) was selected for further study. Some pharmacological properties of 19 are given in Table II and compared with those of flunarizine. . Table II indicates that 19 is a more selective and potent cerebral vasodilator than flunarizine. In both cases, the cerebral vasodilating activities are due to the calcium antagonistic activities. The results of detailed pharmacological characterization of 19 will be reported elsewhere. Table  I .
